SCHEMBL5673973

SCHEMBL5673973

CC1SC(=Nc2cccc(NC(=O)CN(C)C)c2)N(c2ccco2)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.42
MAPT P10636 9/20 0.39
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
HTT P42858 3/20 0.39
LMNA P02545 3/20 0.39
GAA P10253 2/20 0.39
NPSR1 Q6W5P4 2/20 0.37
TNKS O95271 1/20 0.35
PARP1 P09874 1/20 0.35
PARP15 Q460N3 1/20 0.35
PARP14 Q460N5 1/20 0.35
PARP10 Q53GL7 1/20 0.35
PARP12 Q9H0J9 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
PARP4 Q9UKK3 1/20 0.35
PARP3 Q9Y6F1 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340650 0.73 KMT2A (0.53) TAAR1MAPTALDH1A1MEN1KMT2A
SCHEMBL2340642 0.73 KMT2A (0.53) TAAR1MAPTALDH1A1MEN1KMT2A
SCHEMBL5673961 0.68 TAAR1 (0.40) TAAR1MAPTALDH1A1MEN1KMT2A
SCHEMBL14320169 0.68 PARP1 (0.49) TAAR1MAPTMEN1KMT2ALMNA
SCHEMBL12449354 0.65 POLB (0.48) TAAR1MAPTALDH1A1MEN1KMT2A
SCHEMBL19675985 0.61 POLB (0.50) TAAR1MAPTALDH1A1MEN1KMT2A
SCHEMBL13102519 0.61 HPGD (0.62) ALDH1A1MEN1KMT2APOLBL3MBTL1
SCHEMBL1356705 0.60 MAP4K4 (0.48) TAAR1MAPTALDH1A1MEN1KMT2A
SCHEMBL3686435 0.60 KMT2A (0.61) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL2337206 0.60 ALDH1A1 (0.60) TAAR1MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115640-B2 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. (US) 2006-10-03 US disclosed
US-20040180942-A1 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180942-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 TAAR1 481/4885MAPT 4111/4885ALDH1A1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.